Fournier/Serono Esclim
Executive Summary
FDA approves Fournier's estradiol transdermal patch Aug. 4 for the treatment of moderate to severe vasomotor symptoms associated with menopause; vulval and vaginal atrophy; and hypoestrogenism due to hypogonadism, castration, or primary ovarian failure. The drug will be available in five strengths: 0.025, 0.0375, 0.05, 0.075 and 0.1 mg/24 hours. Esclim will be marketed in the U.S. by Ares-Serono